Toshiaki Ohkuma

3.6k total citations · 1 hit paper
62 papers, 2.1k citations indexed

About

Toshiaki Ohkuma is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Surgery. According to data from OpenAlex, Toshiaki Ohkuma has authored 62 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Physiology and 13 papers in Surgery. Recurrent topics in Toshiaki Ohkuma's work include Diabetes Treatment and Management (18 papers), Diabetes Management and Research (10 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Toshiaki Ohkuma is often cited by papers focused on Diabetes Treatment and Management (18 papers), Diabetes Management and Research (10 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Toshiaki Ohkuma collaborates with scholars based in Japan, Australia and United Kingdom. Toshiaki Ohkuma's co-authors include Takanari Kitazono, Udai Nakamura, Mark Woodward, Sanne A. E. Peters, Hiroki Fujii, Hitoshi Ide, Yuji Komorita, Yoichiro Hirakawa, Masanori Iwase and Toshiharu Ninomiya and has published in prestigious journals such as Circulation, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Toshiaki Ohkuma

61 papers receiving 2.0k citations

Hit Papers

Effect of SGLT2 inhibitors on cardiovascular, renal and s... 2019 2026 2021 2023 2019 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis
    2019 227 citations Tadashi Toyama, Brendon L. Neuen et al. Diabetes Obesity and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toshiaki Ohkuma Japan 23 1.1k 392 352 345 328 62 2.1k
Jin‐Shang Wu Taiwan 28 587 0.5× 403 1.0× 325 0.9× 338 1.0× 568 1.7× 66 2.3k
Masanori Iwase Japan 29 965 0.9× 642 1.6× 550 1.6× 395 1.1× 540 1.6× 110 2.6k
Feng‐Hwa Lu Taiwan 28 470 0.4× 419 1.1× 370 1.1× 279 0.8× 529 1.6× 71 2.4k
Jing Hong China 25 885 0.8× 255 0.7× 463 1.3× 295 0.9× 429 1.3× 104 2.0k
Maria Teresa Zanella Brazil 30 810 0.7× 477 1.2× 950 2.7× 299 0.9× 872 2.7× 141 3.2k
Daigo Yoshida Japan 30 371 0.3× 355 0.9× 736 2.1× 247 0.7× 488 1.5× 88 2.7k
Hsiu‐Ching Hsu Taiwan 25 391 0.4× 253 0.6× 255 0.7× 201 0.6× 669 2.0× 72 1.9k
Elisabetta Dall’Aglio Italy 26 1.2k 1.1× 405 1.0× 651 1.8× 406 1.2× 500 1.5× 62 2.6k
Ticiana da Costa Rodrigues Brazil 24 542 0.5× 329 0.8× 283 0.8× 118 0.3× 293 0.9× 90 1.7k
György Jermendy Hungary 26 1.1k 1.0× 391 1.0× 353 1.0× 471 1.4× 530 1.6× 151 2.1k

Countries citing papers authored by Toshiaki Ohkuma

Since Specialization
Citations

This map shows the geographic impact of Toshiaki Ohkuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshiaki Ohkuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshiaki Ohkuma more than expected).

Fields of papers citing papers by Toshiaki Ohkuma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshiaki Ohkuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshiaki Ohkuma. The network helps show where Toshiaki Ohkuma may publish in the future.

Co-authorship network of co-authors of Toshiaki Ohkuma

This figure shows the co-authorship network connecting the top 25 collaborators of Toshiaki Ohkuma. A scholar is included among the top collaborators of Toshiaki Ohkuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshiaki Ohkuma. Toshiaki Ohkuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ohkuma, Toshiaki, et al.. (2025). Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor. Case Reports in Endocrinology. 2025(1). 8872854–8872854.
2.
Ohkuma, Toshiaki, Katie Harris, Mark Woodward, et al.. (2024). Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial. Diabetes Care. 48(2). 279–284. 4 indexed citations
3.
Ohkuma, Toshiaki, Masanori Iwase, Hiroki Fujii, et al.. (2021). Constipation and diabetic kidney disease: The Fukuoka Diabetes Registry. Clinical and Experimental Nephrology. 25(11). 1247–1254. 6 indexed citations
4.
Ohkuma, Toshiaki, Masanori Iwase, Hiroki Fujii, et al.. (2020). Defecation frequency and glycemic control in patients with diabetes: The Fukuoka Diabetes Registry. Journal of Diabetes and its Complications. 35(2). 107751–107751. 6 indexed citations
5.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2020). Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases. 77(1). 23–34.e1. 50 indexed citations
6.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2019). Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology. 30(11). 2229–2242. 101 indexed citations
7.
Toyama, Tadashi, Toshiaki Ohkuma, David J. Handelsman, et al.. (2019). Associations of Impaired Renal Function With Declines in Muscle Strength and Muscle Function in Older Men: Findings From the CHAMP Study. The Journals of Gerontology Series A. 74(11). 1812–1820. 6 indexed citations
8.
9.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2018). Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 138(15). 1537–1550. 188 indexed citations
10.
Rådholm, Karin, John Chalmers, Toshiaki Ohkuma, et al.. (2018). Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: R esults from the ADVANCE‐ON study. Diabetes Obesity and Metabolism. 20(8). 1903–1910. 32 indexed citations
11.
Komorita, Yuji, Masanori Iwase, Hiroki Fujii, et al.. (2018). Impact of Body Weight Loss From Maximum Weight on Fragility Bone Fractures in Japanese Patients With Type 2 Diabetes: The Fukuoka Diabetes Registry. Diabetes Care. 41(5). 1061–1067. 21 indexed citations
12.
Nakamura, Udai, Masanori Iwase, Hiroki Fujii, et al.. (2017). The gene–treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry. BMC Medical Genetics. 18(1). 146–146. 6 indexed citations
13.
Ohkuma, Toshiaki, Masanori Iwase, Hiroki Fujii, et al.. (2017). Joint impact of modifiable lifestyle behaviors on glycemic control and insulin resistance in patients with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetology International. 8(3). 296–305. 1 indexed citations
14.
15.
16.
Ohkuma, Toshiaki, Hiroki Fujii, Masanori Iwase, et al.. (2013). U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: The Fukuoka Diabetes Registry. Metabolism. 63(4). 484–491. 62 indexed citations
17.
18.
Ohkuma, Toshiaki, Hiroki Fujii, Masanori Iwase, et al.. (2012). Impact of eating rate on obesity and cardiovascular risk factors according to glucose tolerance status: the Fukuoka Diabetes Registry and the Hisayama Study. Diabetologia. 56(1). 70–77. 62 indexed citations
19.
Morimoto, Sachio, Masanori Iwase, Yohei Kikuchi, et al.. (2011). Radial augmentation index and diabetic complications in patients with type 2 diabetes mellitus. Diabetology International. 2(3). 127–133. 1 indexed citations
20.
Ohkuma, Toshiaki. (1998). Therapeutic Potential of Insulin-like Growth Factor-I.. Nippon Nōgeikagaku Kaishi. 72(2). 189–192. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin‐Shang Wu Breakdown of academic impact, for papers by Masanori Iwase Breakdown of academic impact, for papers by Feng‐Hwa Lu Breakdown of academic impact, for papers by Jing Hong Breakdown of academic impact, for papers by Maria Teresa Zanella Breakdown of academic impact, for papers by Daigo Yoshida Breakdown of academic impact, for papers by Hsiu‐Ching Hsu Breakdown of academic impact, for papers by Elisabetta Dall’Aglio Breakdown of academic impact, for papers by Ticiana da Costa Rodrigues Breakdown of academic impact, for papers by György Jermendy
Rankless by CCL
2026